Merus N.V.
NASDAQ:MRUS
Overview | Financials
| Company Name | Merus N.V. |
| Symbol | MRUS |
| Currency | USD |
| Price | 67.19 |
| Market Cap | 5,081,875,336 |
| Dividend Yield | 0% |
| 52-week-range | 33.19 - 69.2 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Sven Ante Lundberg M.D. |
| Website | https://www.merus.nl |
An error occurred while fetching data.
About Merus N.V.
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD







